Back to search
FDAFDA · Food and drugs·Recall number D-1066-2013

Ifosfamide Injection 3g/60 mL, Single dose vial, Rx only, Sterile, For Intravenous Use, Refrigerate at 2-8 degrees celcius, Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017, NDC 0069-4496-22

Published October 9, 2013 · Recall initiated: September 13, 2013

Summary

FDA records drug Class II recall D-1066-2013, published October 9, 2013 and initiated September 13, 2013. Recalling firm: AmeriSource Bergen; Status: Terminated; Reported quantity: 60 vials; Lot: Lot #s: 7800929, 7800931, Exp 02/15; 7800962, Exp 03/15. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Temperature abuse: Certain vials of Ifosfamide IV products were not refrigerated at certain Amerisource Bergen Drug Corp distribution centers.

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
AmeriSource Bergen
Distributor
Nationwide
Lot
Lot #s: 7800929, 7800931, Exp 02/15; 7800962, Exp 03/15
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Ifosfamide Injection 3g/60 mL, Single dose vial, Rx only, Sterile, For Intravenous Use, Refrigerate at 2-8 degrees celcius, Distributed by Pfizer Labs, Division of Pfizer Inc., New York, NY 10017, NDC 0069-4496-22 recalled?

Yes. FDA published recall D-1066-2013 on October 9, 2013. Reported hazard: Temperature abuse: Certain vials of Ifosfamide IV products were not refrigerated at certain Amerisource Bergen Drug Corp distribution centers.

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit